Apolipoprotein CIII inhibition in partial lipodystrophy

National Institute Of Diabetes And Digestive And Kidney Diseases

Investigators

Abstract

In the past fiscal year, analyses of the main study outcomes were completed. 5 subjects with partial lipodystrophy participated in the study. Compared to prior to study drug, 16 weeks of apoCIII inhibition in subjects with lipodystrophy decreased fasting plasma triglycerides by 57%, and decreased serum apoCIII by 61%, with high correlation between triglyceride and apoCIII concentrations. Activation of lipoprotein lipase by subjects' serum increased after apoCIII inhibition. Although hemoglobin A1c did not change, there were improvements in multiorgan insulin sensitivity (muscle, liver, and adipose) in most subjects.